Table of Contents
Chapter 1 Research Technologyology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Technologyology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Stem Cells Market Market Variables, Trends, & Scope
4.1 Stem Cells Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Ongoing Developments In Regenerative Medicine
4.4.2 Rising Funds For Accelerating Stem Cell Research
4.4.3 Growing Demand For Stem Cell Banking
4.4.4 Increasing Prevalence Of Genetic Disorders
4.5 Market Restraint Analysis
4.5.1 Ethical Concern Related To Stem Cell Research
4.5.1 Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
4.6 Key Opportunities
4.6.1 Demand For Cell & Gene Therapies
4.7 Key Challenge
4.7.1 Technical Limitations Associated With Manufacturing Processes
4.8 Stem Cells Market – Pestle Analysis
4.9 Industry Analysis – Porter’s
4.10 Major Deals And Strategic Alliances Analysis
4.10.1 Joint Ventures
4.10.2 Mergers And Acquisitions
4.10.3 Licensing And Partnership
4.10.4 Technology Collaborations
4.10.5 Strategic Divestments
4.11 COVID-19 Impact Analysis
Chapter 5 Stem Cells Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Global Stem Cells Market: Product Movement Analysis
5.2 Adult Stem Cells (ASCs)
5.2.1 Adult Stem Cells (Ascs) Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2 Hematopoietic Stem Cells (Blood Stem Cells)
5.2.2.1 Hematopoietic stem cells (blood stem cells) market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.3 Mesenchymal Stem Cells
5.2.3.1 Mesenchymal stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.4 Neural Stem Cells
5.2.4.1 Neural stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.5 Epithelial/Skin Stem Cells
5.2.5.1 Epithelial/Skin stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.6 Other Adult Stem Cells
5.2.6.1 Other adult stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.3 Human Embryonic Stem Cells
5.3.1 Human Embryonic Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Induced Pluripotent Stem Cells
5.4.1 Induced Pluripotent Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5 Very Small Embryonic Like Stem Cells
5.5.1 Very Small Embryonic Like Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Stem Cells Market- Segment Analysis, by Application, 2018 – 2030 (USD Million)
6.1 Stem Cells Market: Application Movement Analysis
6.2 Regenerative Medicine
6.2.1 Regenerative Medicine Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.2.2 Neurology
6.2.2.1 Neurology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.3 Orthopedics
6.2.3.1 Orthopedics market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.4 Oncology
6.2.4.1 Oncology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.5 Hematology
6.2.5.1 Hematology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.6 Cardiovascular and Myocardial Infraction
6.2.6.1 Cardiovascular and myocardial infraction market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.7 Injuries
6.2.7.1 Injuries market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.8 Diabetes
6.2.8.1 Diabetes market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.9 Liver Disorder
6.2.9.1 Liver Disorder market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.10 Incontinence
6.2.10.1 Incontinence market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.11 Others
6.2.11.1 Others market estimates and forecasts, 2018 – 2030 (USD Million)
6.3 Drug Discovery and Development
6.3.1 Drug Discovery And Development Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Stem Cells Market – Segment Analysis, by Technology, 2018 – 2030 (USD Million)
7.1 Global Stem Cells Market: Technology Movement Analysis
7.2 Cell Acquisition
7.2.1 Cell Acquisition Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2 Bone Marrow Harvest
7.2.2.1 Bone Marrow Harvest market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.3 Umbilical Blood Cord
7.2.3.1 Umbilical Blood Cord market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.4 Apheresis
7.2.4.1 Apheresis market estimates and forecasts, 2018 – 2030 (USD Million)
7.3 Cell Production
7.3.1 Cell Production Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.2 Therapeutic Cloning
7.2.3.1 Therapeutic Cloning market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.3 In Vitro Fertilization
7.3.3.1 In Vitro Fertilization market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.4 Cell Culture
7.3.4.1 Cell Culture market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.5 Isolation
7.3.5.1 Isolation market estimates and forecasts, 2018 – 2030 (USD Million)
7.4 Cryopreservation
7.4.1 Cryopreservation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5 Expansion And Sub-Culture
7.5.1 Expansion And Sub-Culture Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Stem Cells Market – Segment Analysis, By Therapy, 2018 – 2030 (USD Million)
8.1 Global Stem Cells Market: Therapy Movement Analysis
8.2 Autologous
8.2.1 Autologous Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3 Allogenic
8.3.1 Allogenic Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 9 Stem Cells Market – Segment Analysis, By End-User, 2018 – 2030 (USD Million)
9.1 Global Stem Cells Market: End-User Movement Analysis
9.2 Pharmaceutical And Biotechnology Companies
9.2.1 Pharmaceutical And Biotechnology Companies Market Estimates And Forecast, 2018 – 2030 (USD Million)
9.3 Hospitals & Cell Banks
9.3.1 Hospitals & Cell Banks Market Estimates And Forecast, 2018 – 2030 (USD Million)
9.4 Academic & Research Institutes
9.4.1 Academic & Research Institutes Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 10 Stem Cells Market: – Segment Analysis, By Region, 2018 – 2030 (USD Million)
10.1 Stem Cells Market: Regional Movement Analysis
10.2 North America
10.2.1 North America Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.2.2 U.S.
10.2.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
10.2.3 Canada
10.2.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
10.3 Europe
10.3.1 Europe Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.3.2 U.K.
10.3.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
10.3.3. Germany
10.3.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
10.3.4 France
10.3.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
10.3.5. Italy
10.3.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
10.3.5 Spain
10.3.5.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
10.4 Asia Pacific
10.4.1 Asia Pacific Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.2 Japan
10.4.2.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
10.4.3 China
10.4.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
10.4.4 India
10.4.4.1 India Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.5 South Korea
10.4.5.1 South Korea Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.6 Australia
10.4.6.1 Australia Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5 Latin America
10.5.1 Latin America Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.3 Mexico
10.5.3.1 Mexico Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.4 Argentina
10.5.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
10.6 Middle East & Africa (MEA)
10.6.1 Middle East & Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.6.1 South Africa
10.6.1.1 South Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.6.2 Saudi Arabia
10.6.2.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
10.6.3 UAE
10.6.3.1 UAE market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 11 Competitive Landscape
11.1 Public Companies
11.1.1 Company Market Position Analysis
11.1.2 Competitive Dashboard Analysis
11.1.3 Strategic Framework
11.2 Private Companies
11.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
11.2.2 Regional Network Map
11.3 Company Profiles
11.3.1 ADVANCED CELL TECHNOLOGY, INC.
11.3.1.1 Company Overview
11.3.1.2 Financial Performance
11.3.1.3 Product Benchmarking
11.3.1.4 Strategic Initiatives
11.3.2 STEMCELL Technologies, Inc.
11.3.2.1 Company Overview
11.3.2.2 Financial Performance
11.3.2.3 Product Benchmarking
11.3.2.4 Strategic Initiatives
11.3.3 CELLULAR ENGINEERING TECHNOLOGIES INC.
11.3.3.1 Company Overview
11.3.3.2 Financial Performance
11.3.3.3 Product Benchmarking
11.3.3.4 Strategic Initiatives
11.3.4 CELLGENIX GmbH
11.3.4.1 Company Overview
11.3.4.2 Financial Performance
11.3.4.3 Product Benchmarking
11.3.4.4 Strategic Initiatives
11.3.5 PROMOCELL GMBH
11.3.5.1 Company Overview
11.3.5.2 Financial Performance
11.3.5.3 Product Benchmarking
11.3.5.4 Strategic Initiatives
11.3.6 LONZA
11.3.6.1 Company Overview
11.3.6.2 Financial Performance
11.3.6.3 Product Benchmarking
11.3.6.4 Strategic Initiatives
11.3.7 KITE PHARMA
11.3.7.1 Company Overview
11.3.7.2 Financial Performance
11.3.7.3 Product Benchmarking
11.3.7.4 Strategic Initiatives
11.3.8 CELLARTIS AB
11.3.8.1 Company Overview
11.3.8.2 Financial Performance
11.3.8.3 Product Benchmarking
11.3.8.4 Strategic Initiatives
11.3.9 ANGEL BIOTECHNOLOGY
11.3.9.1 Company Overview
11.3.9.2 Financial Performance
11.3.9.3 Product Benchmarking
11.3.9.4 Strategic Initiatives
11.3.10 BRAINSTORM CELL THERAPEUTICS
11.3.10.1 Company Overview
11.3.10.2 Financial Performance
11.3.10.3 Product Benchmarking
11.3.10.4 Strategic Initiatives
11.3.11 CELGENE CORPORATION
11.3.11.1 Company Overview
11.3.11.2 Financial Performance
11.3.11.3 Product Benchmarking
11.3.11.4 Strategic Initiatives
11.3.12 OSIRIS THERAPEUTICS, INC.
11.3.12.1 Company Overview
11.3.12.2 Financial Performance
11.3.12.3 Product Benchmarking
11.3.12.4 Strategic Initiatives
11.3.13 GENEA BIOCELLS
11.3.13.1 Company Overview
11.3.13.2 Financial Performance
11.3.13.3 Product Benchmarking
11.3.13.4 Strategic Initiatives
11.3.14 BIOHEART INC.
11.3.14.1 Company Overview
11.3.14.2 Financial Performance
11.3.14.3 Product Benchmarking
11.3.14.4 Strategic Initiatives
11.3.15 WAISMAN BIOMANUFACTURING
11.3.15.1 Company Overview
11.3.15.2 Financial Performance
11.3.15.3 Product Benchmarking
11.3.15.4 Strategic Initiatives
11.3.16 TIGENIX
11.3.16.1 Company Overview
11.3.16.2 Financial Performance
11.3.16.3 Product Benchmarking
11.3.16.4 Strategic Initiatives
11.3.17 CALADRIUS
11.3.17.1 Company Overview
11.3.17.2 Financial Performance
11.3.17.3 Product Benchmarking
11.3.17.4 Strategic Initiatives
11.3.18 GAMIDA CELL.
11.3.18.1 Company Overview
11.3.18.2 Financial Performance
11.3.18.3 Product Benchmarking
11.3.18.4 Strategic Initiatives
11.3.19 PLURISTEM THERAPEUTICS INC.
11.3.19.1 Company Overview
11.3.19.2 Financial Performance
11.3.19.3 Product Benchmarking
11.3.19.4 Strategic Initiatives